Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $260
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $250 to $260.
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $250 to $260.